These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10977388)

  • 1. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.
    Sculpher M; Fenwick E; Claxton K
    Pharmacoeconomics; 2000 May; 17(5):461-77. PubMed ID: 10977388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
    Philips Z; Bojke L; Sculpher M; Claxton K; Golder S
    Pharmacoeconomics; 2006; 24(4):355-71. PubMed ID: 16605282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the validity of cost-effectiveness models.
    McCabe C; Dixon S
    Pharmacoeconomics; 2000 May; 17(5):501-13. PubMed ID: 10977390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.
    Cooper NJ; Sutton AJ; Abrams KR
    Stat Methods Med Res; 2002 Dec; 11(6):491-512. PubMed ID: 12516986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using health state utility values in models exploring the cost-effectiveness of health technologies.
    Ara R; Wailoo A
    Value Health; 2012; 15(6):971-4. PubMed ID: 22999149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases : a review and suggested reporting framework.
    Haji Ali Afzali H; Gray J; Karnon J
    Appl Health Econ Health Policy; 2013 Apr; 11(2):85-93. PubMed ID: 23456647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedicated Perioperative Hip Fracture Comanagement Programs are Cost-effective in High-volume Centers: An Economic Analysis.
    Swart E; Vasudeva E; Makhni EC; Macaulay W; Bozic KJ
    Clin Orthop Relat Res; 2016 Jan; 474(1):222-33. PubMed ID: 26260393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Handling uncertainty in cost-effectiveness models.
    Briggs AH
    Pharmacoeconomics; 2000 May; 17(5):479-500. PubMed ID: 10977389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
    Grieve R; Hutton J; Green C
    Health Policy; 2003 Jun; 64(3):311-24. PubMed ID: 12745170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analytic modeling in spinal surgery: a methodologic overview with review of current published literature.
    McAnany SJ; Anwar MA; Qureshi SA
    Spine J; 2015 Oct; 15(10):2254-70. PubMed ID: 26111597
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.